These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 25360799)

  • 21. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway.
    Liu S; Vinall RL; Tepper C; Shi XB; Xue LR; Ma AH; Wang LY; Fitzgerald LD; Wu Z; Gandour-Edwards R; deVere White RW; Kung HJ
    Oncogene; 2008 Jan; 27(4):499-505. PubMed ID: 17653089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT.
    Kuo YY; Huo C; Li CY; Chuu CP
    Cancer Gene Ther; 2024 Jun; 31(6):807-815. PubMed ID: 38480977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z; Chen S; Sowalsky AG; Voznesensky OS; Mostaghel EA; Nelson PS; Cai C; Balk SP
    Clin Cancer Res; 2014 Mar; 20(6):1590-600. PubMed ID: 24449822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
    Cortés MA; Cariaga-Martinez AE; Lobo MV; Martín Orozco RM; Motiño O; Rodríguez-Ubreva FJ; Angulo J; López-Ruiz P; Colás B
    Carcinogenesis; 2012 Jun; 33(6):1169-77. PubMed ID: 22461520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.
    Rokhlin OW; Taghiyev AF; Bayer KU; Bumcrot D; Koteliansk VE; Glover RA; Cohen MB
    Cancer Biol Ther; 2007 May; 6(5):732-42. PubMed ID: 17387273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
    Shorning BY; Dass MS; Smalley MJ; Pearson HB
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.
    Kita K; Shiota M; Tanaka M; Otsuka A; Matsumoto M; Kato M; Tamada S; Iwao H; Miura K; Nakatani T; Tomita S
    Cancer Sci; 2017 Sep; 108(9):1820-1827. PubMed ID: 28691182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer.
    Dong Z; Liu Y; Lu S; Wang A; Lee K; Wang LH; Revelo M; Lu S
    Mol Endocrinol; 2006 Oct; 20(10):2315-25. PubMed ID: 16762975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
    Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
    Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
    Murillo H; Huang H; Schmidt LJ; Smith DI; Tindall DJ
    Endocrinology; 2001 Nov; 142(11):4795-805. PubMed ID: 11606446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway.
    Lee SO; Lou W; Hou M; Onate SA; Gao AC
    Oncogene; 2003 Sep; 22(39):7981-8. PubMed ID: 12970746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
    De Velasco MA; Kura Y; Sakai K; Hatanaka Y; Davies BR; Campbell H; Klein S; Kim Y; MacLeod AR; Sugimoto K; Yoshikawa K; Nishio K; Uemura H
    JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
    Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
    Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
    Hakariya T; Shida Y; Sakai H; Kanetake H; Igawa T
    Biochem Biophys Res Commun; 2006 Mar; 342(1):92-100. PubMed ID: 16472761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of the androgen receptor splicing in prostate cancer cells.
    Liu LL; Xie N; Sun S; Plymate S; Mostaghel E; Dong X
    Oncogene; 2014 Jun; 33(24):3140-50. PubMed ID: 23851510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.